Gene therapy for alpha-1 antitrypsin deficiency lung disease

Maria J. Chiuchiolo, Ronald Crystal

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Alpha-1 antitrypsin (AAT) deficiency, characterized by low plasma levels of the serine protease inhibitor AAT, is associated with emphysema secondary to insufficient protection of the lung from neutrophil proteases. Although AAT augmentation therapy with purified AAT protein is efficacious, it requires weekly to monthly intravenous infusion of AAT purified from pooled human plasma, has the risk of viral contamination and allergic reactions, and is costly. As an alternative, gene therapy offers the advantage of single administration, eliminating the burden of protein infusion, and reduced risks and costs. The focus of this review is to describe the various strategies forAAT gene therapy for the pulmonary manifestations of AAT deficiency and the state of the art in bringing AAT gene therapy to the bedside.

Original languageEnglish
Pages (from-to)S352-S369
JournalAnnals of the American Thoracic Society
Volume13
DOIs
Publication statusPublished - 1 Aug 2016
Externally publishedYes

Fingerprint

alpha 1-Antitrypsin Deficiency
Deficiency Diseases
alpha 1-Antitrypsin
Genetic Therapy
Lung Diseases
Lung
Serine Proteinase Inhibitors
Emphysema
Complementary Therapies
Intravenous Infusions
Hypersensitivity
Proteins
Neutrophils
Peptide Hydrolases
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Costs and Cost Analysis

Keywords

  • Adeno-associated vector
  • Adenovirus vectors
  • Alpha-1 antytripsin deficiency
  • Gene therapy
  • Lung disease

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Gene therapy for alpha-1 antitrypsin deficiency lung disease. / Chiuchiolo, Maria J.; Crystal, Ronald.

In: Annals of the American Thoracic Society, Vol. 13, 01.08.2016, p. S352-S369.

Research output: Contribution to journalArticle

@article{e7245228f6d8475f8866b70ffe6ad66d,
title = "Gene therapy for alpha-1 antitrypsin deficiency lung disease",
abstract = "Alpha-1 antitrypsin (AAT) deficiency, characterized by low plasma levels of the serine protease inhibitor AAT, is associated with emphysema secondary to insufficient protection of the lung from neutrophil proteases. Although AAT augmentation therapy with purified AAT protein is efficacious, it requires weekly to monthly intravenous infusion of AAT purified from pooled human plasma, has the risk of viral contamination and allergic reactions, and is costly. As an alternative, gene therapy offers the advantage of single administration, eliminating the burden of protein infusion, and reduced risks and costs. The focus of this review is to describe the various strategies forAAT gene therapy for the pulmonary manifestations of AAT deficiency and the state of the art in bringing AAT gene therapy to the bedside.",
keywords = "Adeno-associated vector, Adenovirus vectors, Alpha-1 antytripsin deficiency, Gene therapy, Lung disease",
author = "Chiuchiolo, {Maria J.} and Ronald Crystal",
year = "2016",
month = "8",
day = "1",
doi = "10.1513/AnnalsATS.201506-344KV",
language = "English",
volume = "13",
pages = "S352--S369",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",

}

TY - JOUR

T1 - Gene therapy for alpha-1 antitrypsin deficiency lung disease

AU - Chiuchiolo, Maria J.

AU - Crystal, Ronald

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Alpha-1 antitrypsin (AAT) deficiency, characterized by low plasma levels of the serine protease inhibitor AAT, is associated with emphysema secondary to insufficient protection of the lung from neutrophil proteases. Although AAT augmentation therapy with purified AAT protein is efficacious, it requires weekly to monthly intravenous infusion of AAT purified from pooled human plasma, has the risk of viral contamination and allergic reactions, and is costly. As an alternative, gene therapy offers the advantage of single administration, eliminating the burden of protein infusion, and reduced risks and costs. The focus of this review is to describe the various strategies forAAT gene therapy for the pulmonary manifestations of AAT deficiency and the state of the art in bringing AAT gene therapy to the bedside.

AB - Alpha-1 antitrypsin (AAT) deficiency, characterized by low plasma levels of the serine protease inhibitor AAT, is associated with emphysema secondary to insufficient protection of the lung from neutrophil proteases. Although AAT augmentation therapy with purified AAT protein is efficacious, it requires weekly to monthly intravenous infusion of AAT purified from pooled human plasma, has the risk of viral contamination and allergic reactions, and is costly. As an alternative, gene therapy offers the advantage of single administration, eliminating the burden of protein infusion, and reduced risks and costs. The focus of this review is to describe the various strategies forAAT gene therapy for the pulmonary manifestations of AAT deficiency and the state of the art in bringing AAT gene therapy to the bedside.

KW - Adeno-associated vector

KW - Adenovirus vectors

KW - Alpha-1 antytripsin deficiency

KW - Gene therapy

KW - Lung disease

UR - http://www.scopus.com/inward/record.url?scp=84989857176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989857176&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201506-344KV

DO - 10.1513/AnnalsATS.201506-344KV

M3 - Article

C2 - 27564673

AN - SCOPUS:84989857176

VL - 13

SP - S352-S369

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

ER -